The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Combination Antifungal Therapy for Invasive Aspergillosis
Open accessAbstract
BACKGROUND: Aspergillosis therapy with amphotericin, azoles, or echinocandins is associated with substantial mortality, ranging from 30% to 80%, depending on the stage of infection and the host's underlying disease. The results of in vitro studies and animal models suggest that combination therapy with azoles and echinocandins may have additive activity against Aspergillus species. METHODS: We evaluated the outcomes of patients with aspergillosis who experienced failure of initial therapy with amphotericin B formulations and received either voriconazole (n=31) or a combination of voriconazole and caspofungin (n=16) for salvage therapy. RESULTS: The combination of voriconazole and caspofungin was associated with improved 3-month survival rate, compared with voriconazole alone (hazard ratio [HR], 0.42; 95% confidence interval [CI], 0.17-1.1; P=.048). In multivariable models, salvage therapy with the combination of voriconazole and caspofungin was associated with reduced mortality, compared with therapy with voriconazole (HR, 0.28; 95% CI, 0.28-0.92; P=.011), independent of other prognostic variables (e.g., receipt of transplant and type of conditioning therapy). The probability of death due to aspergillosis was lowest in patients who received the combination regimen. CONCLUSIONS: Randomized trials are warranted to determine whether this combination should be used as primary therapy for aspergillosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Self-citationAscioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331
Epidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients
Marr, K. A., Carter, R. A., Crippa, F., Wald, A., & Corey, L. (2002) · Clinical Infectious Diseases · doi:10.1086/339202 · Cited by 1,448
Self-citationAspergillosis Case-Fatality Rate: Systematic Review of the Literature
Lin, S.-J., Schranz, J., & Teutsch, S. M. (2001) · Clinical Infectious Diseases · doi:10.1086/318483 · Cited by 1,409
McSweeney, P. A., Niederwieser, D., Shizuru, J. A., Sandmaier, B. M., Molina, A. J., Maloney, D. G., Chauncey, T. R., Gooley, T. A., Hegenbart, U., Nash, R. A., et al. (2001) · Blood · doi:10.1182/blood.v97.11.3390 · Cited by 1,389
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., & Corey, L. (2002) · Blood · doi:10.1182/blood-2002-05-1496 · Cited by 957
Self-citationEfficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
Denning, D. W., Ribaud, P., Milpied, N., Caillot, D., Herbrecht, R., Thiel, E., Haas, A., Ruhnke, M., & Lode, H. (2002) · Clinical Infectious Diseases · doi:10.1086/324620 · Cited by 844 · cited 1×
“However, outcomes remain poor, especially in hematopoietic stem cell transplant (HSCT) recipients, with studies demonstrating favorable responses in only 20%–40% of such patients after 3 months of salvage therapy [6, 7].”
BackgroundInvasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes
Patterson, T. F., Kirkpatrick, W. R., White, M., Hiemenz, J. W., WINGARD, J. R., DUPONT, B., RINALDI, M. G., STEVENS, D. A., & Graybill, J. R. (2000) · Medicine · doi:10.1097/00005792-200007000-00006 · Cited by 791
Cited by
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926
Self-citationWalsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,706
Self-citationUllmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.002 · Cited by 1,556
Pulmonary aspergillosis: a clinical review
Kousha, M., Tadi, R., & Soubani, A. O. (2011) · European Respiratory Review · doi:10.1183/09059180.00001011 · Cited by 752
Nosocomial fungal infections: epidemiology, diagnosis, and treatment
Perlroth, J., Choi, B., & Spellberg, B. (2007) · Medical Mycology · doi:10.1080/13693780701218689 · Cited by 738
Segal, B. H. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0808853 · Cited by 661
Limper, A. H., Knox, K. S., Sarosi, G. A., Ampel, N. M., Bennett, J. E., Catanzaro, A., Davies, S. F., Dismukes, W. E., Hage, C. A., Marr, K. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2008-740st · Cited by 612
Self-citationAspergillus Infections in Transplant Recipients
Singh, N., & Paterson, D. L. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.1.44-69.2005 · Cited by 579
Combination antifungal therapy
Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., & Rex, J. H. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.693-715.2004 · Cited by 541
Combination Antifungal Therapy for Invasive Aspergillosis: A Randomized Trial
Marr, K. A., Schlamm, H. T., Herbrecht, R., Rottinghaus, S. T., Bow, E. J., Cornely, O. A., Heinz, W. J., Jagannatha, S., Koh, L. P., Kontoyiannis, D. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m13-2508 · Cited by 514
Self-citationUpton, A., Kirby, K. A., Carpenter, P., Boeckh, M., & Marr, K. A. (2007) · Clinical Infectious Diseases · doi:10.1086/510592 · Cited by 514
Self-citationSegal, B. H., Herbrecht, R., Stevens, D. A., Ostrosky‐Zeichner, L., Sobel, J., Viscoli, C., Walsh, T. J., Maertens, J., Patterson, T. F., Perfect, J. R., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/590566 · Cited by 468
Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease
Bulpa, P., Dive, A., & Sibille, Y. (2007) · European Respiratory Journal · doi:10.1183/09031936.00062206 · Cited by 466
Groll, A. H., Castagnola, E., Cesaro, S., Dalle, J.-H., Engelhard, D., Hope, W., Roilides, E., Styczynski, J., Warris, A., & Lehrnbecher, T. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70017-8 · Cited by 407
Improved outcome in central nervous system aspergillosis, using voriconazole treatment
Schwartz, S. (2005) · Blood · doi:10.1182/blood-2005-02-0733 · Cited by 391
Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
Bellmann, R., & Smuszkiewicz, P. (2017) · Infection · doi:10.1007/s15010-017-1042-z · Cited by 389
Echinocandin Antifungal Drugs in Fungal Infections: A Comparison
Chen, S. C.-A., Slavin, M. A., & Sorrell, T. C. (2011) · Drugs · doi:10.2165/11585270-000000000-00000 · Cited by 371
Prevention and Treatment of Cancer-Related Infections
Baden, L. R., Bensinger, W., Angarone, M., Casper, C., Dubberke, E. R., Freifeld, A. G., Garzon, R., Greene, J. N., Greer, J. P., Ito, J. I., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0146 · Cited by 368
Self-citationInvasive Aspergillosis: Epidemiology, Diagnosis and Management in Immunocompromised Patients
Maschmeyer, G., Haas, A., & Cornely, O. A. (2007) · Drugs · doi:10.2165/00003495-200767110-00004 · Cited by 366
Nett, J. E., & Andes, D. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.012 · Cited by 351
Singh, N., Limaye, A. P., Forrest, G., Safdar, N., Mu??oz, P., Pursell, K., Houston, S., Rosso, F., Montoya, J. G., Patton, P., et al. (2006) · Transplantation · doi:10.1097/01.tp.0000202421.94822.f7 · Cited by 336
Current Approaches to Diagnosis and Treatment of Invasive Aspergillosis
Segal, B. H., & Walsh, T. J. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200505-727so · Cited by 334
Meletiadis, J., Pournaras, S., Roilides, E., & Walsh, T. J. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00999-09 · Cited by 325
Factors associated with mortality in transplant patients with invasive aspergillosis
Baddley, J. W., Andes, D. R., Marr, K. A., Kontoyiannis, D. P., Alexander, B. D., Kauffman, C. A., Oster, R. A., Anaissie, E. J., Walsh, T. J., Schuster, M. G., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/652768 · Cited by 303
Self-citationPulmonary aspergillosis: a clinical update
Zmeili, O. S., & Soubani, A. O. (2007) · QJM · doi:10.1093/qjmed/hcm035 · Cited by 278
Voriconazole in the treatment of fungal eye infections: a review of current literature
Hariprasad, S. M., Mieler, W. F., Lin, T. K., Sponsel, W. E., & Graybill, J. R. (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.136515 · Cited by 263
Mousset, S., Buchheidt, D., Heinz, W., Ruhnke, M., Cornely, O. A., Egerer, G., Krüger, W., Link, H., Neumann, S., Ostermann, H., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-013-1867-1 · Cited by 255
Echinocandins: The newest class of antifungals
Sucher, A. J., Chahine, E. B., & Balcer, H. E. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m237 · Cited by 213
Cappelletty, D., & Eiselstein‐McKitrick, K. (2007) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.3.369 · Cited by 205
Aspergillosis: Spectrum of Disease, Diagnosis, and Treatment
Barnes, P. D., & Marr, K. A. (2006) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2006.06.001 · Cited by 205
Self-citationCaillot, D., Thiébaut, A., Herbrecht, R., de Botton, S., Pigneux, A., Bernard, F., Larché, J., Monchecourt, F., Alfandari, S., & Mahi, L. (2007) · Cancer · doi:10.1002/cncr.23109 · Cited by 190
Current status of antifungal susceptibility testing methods
Arikan, S. (2007) · Medical Mycology · doi:10.1080/13693780701436794 · Cited by 152
Antifungal Pharmacokinetics and Pharmacodynamics
Lepak, A. J., & Andes, D. R. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019653 · Cited by 134
Echinocandins: the expanding antifungal armamentarium
Aguilar-Zapata, D., Petraitiene, R., & Petraitis, V. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ814 · Cited by 112
Ghannoum, M., Long, L., Larkin, E. L., Isham, N., Sherif, R., Borroto-Esoda, K., Barat, S., & Angulo, D. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00244-18 · Cited by 80
Zilberberg, M. D., & Shorr, A. F. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2009.04.008 · Cited by 42
Seyedmousavi, S., Meletiadis, J., Melchers, W. J. G., Rijs, A. J. M. M., Mouton, J. W., & Verweij, P. E. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00980-12 · Cited by 38
Fluvastatin potentiates the activity of caspofungin against Aspergillus fumigatus in vitro
Natesan, S. K., Chandrasekar, P. H., Alangaden, G. J., & Manavathu, E. K. (2008) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2007.10.015 · Cited by 32
Invasive Aspergillosis in Hematological Patients
Kimura, S.-I. (2016) · Medical Mycology Journal · doi:10.3314/mmj.57.j77 · Cited by 14
Metadata
- Authors
- Marr, K. A., Boeckh, M., Carter, R. A., Kim, H. W., & Corey, L.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-09-15
- Volume
- 39
- Issue
- 6
- Pages
- 797-802
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2102584901
- Cited by
- 596
- References
- 35
- FWCI
- 37.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.